{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:43:30Z","timestamp":1760550210425,"version":"3.40.5"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.ejca.2016.12.026","type":"journal-article","created":{"date-parts":[[2017,2,17]],"date-time":"2017-02-17T04:06:12Z","timestamp":1487304372000},"page":"56-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit"],"prefix":"10.1016","volume":"75","author":[{"given":"Dionysis","family":"Papadatos-Pastos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Desam","family":"Roda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jose","family":"De Miguel Luken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Petruckevitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Awais","family":"Jalil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Capelan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasiliki","family":"Michalarea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joao","family":"Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Diamantis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaishree","family":"Bhosle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Rhoda","family":"Molife","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udai","family":"Banerji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johann S.","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2087-4963","authenticated-orcid":false,"given":"Sanjay","family":"Popat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary E.R.","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy A.","family":"Yap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2016.12.026_bib1","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.bjc.6602307","article-title":"The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050 (link is external)","volume":"92","author":"Hodgson","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2016.12.026_bib2","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jtcvs.2014.10.041","article-title":"Pleurectomy\/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: a 10-year experience","volume":"149","author":"Lang-Lazdunski","year":"2015","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ejca.2016.12.026_bib3","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"French cooperative thoracic intergroup (IFCT). Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2016.12.026_bib4","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2016.12.026_bib5","doi-asserted-by":"crossref","first-page":"7040","DOI":"10.1200\/jco.2010.28.15_suppl.7040","article-title":"A retrospective analysis of second-line chemotherapy for malignant pleural mesothelioma (MPM)","volume":"28","author":"La Verde","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2016.12.026_bib6","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.lungcan.2008.04.001","article-title":"The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma","volume":"63","author":"Stebbing","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2016.12.026_bib7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.lungcan.2014.03.006","article-title":"Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma","volume":"84","author":"Zauderer","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2016.12.026_bib8","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1038\/bjc.2014.220","article-title":"Multipoint targeting of the PI3K\/mTOR pathway in mesothelioma","volume":"110","author":"Zhou","year":"2014","journal-title":"Br J Cancer"},{"issue":"237","key":"10.1016\/j.ejca.2016.12.026_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008639","article-title":"Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship","volume":"6","author":"Shapiro","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ejca.2016.12.026_bib10","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1158\/1535-7163.MCT-09-0138","article-title":"The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in\u00a0vitro and in\u00a0vivo with particular efficacy for small cell lung cancer","volume":"8","author":"Crisanti","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2016.12.026_bib11","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1200\/JCO.2008.19.5081","article-title":"Prospective validation of a prognostic score to improve patient selection for oncology phase I trials","volume":"27","author":"Arkenau","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2016.12.026_bib12","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/bjc.2015.67","article-title":"The neutrophil-lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials","volume":"112","author":"Kumar","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2016.12.026_bib13","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1001\/jama.292.17.2130","article-title":"Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials","volume":"292","author":"Roberts","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2016.12.026_bib14","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMsa042220","article-title":"Risks and benefits of phase 1 oncology trials, 1991 through 2002","volume":"352","author":"Horstmann","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2016.12.026_bib15","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2010.28.15_suppl.2519","article-title":"Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single-center experience","volume":"28","author":"Alam","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2016.12.026_bib16","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1093\/annonc\/mds030","article-title":"Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience","volume":"23","author":"Molife","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2016.12.026_bib17","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.lungcan.2014.05.006","article-title":"Efficacy of phase 1 trials in malignant pleural mesothelioma: description of a series of patients at a single institution","volume":"85","author":"Raphael","year":"2014","journal-title":"Lung Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917300424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917300424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T03:25:52Z","timestamp":1536031552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917300424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":17,"alternative-id":["S0959804917300424"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2016.12.026","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2016.12.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}